Cytotoxic T lymphocyte responses to vaccinia virus antigens but not HIV-1 subtype E envelope protein seen in HIV-1 seronegative Thais.
Asian Pac J Allergy Immunol
;
2001 Mar; 19(1): 17-22
Article
Dans Anglais
| IMSEAR
| ID: sea-36710
ABSTRACT
The HIV-1 prime boost phase I/II vaccine trial using a recombinant canarypox vector, vCP1521, containing subtype E env (gp120), and subtype B env (gp41), gag and protease has started in Thailand. We have demonstrated that although 4 from 15 human immunodeficiency virus type 1 (HIV-1) seronegative Individuals showed cytotoxic T lymphocyte (CTL) responses to vaccinia virus antigens, none of them showed specific CTL responses to subtype E Env after in vitro stimulation. This preliminary study suggests that specific CTL responses to subtype E envelope detected in HIV-1 seronegative Individuals after vaccination should be considered as specific responses to the immunization.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Valeurs de référence
/
Thaïlande
/
Virus de la vaccine
/
Femelle
/
Humains
/
Mâle
/
Lymphocytes B
/
Lymphocytes T cytotoxiques
/
Antigènes du VIH
/
Protéine d'enveloppe gp120 du VIH
Type d'étude:
Etude diagnostique
Pays comme sujet:
Asie
langue:
Anglais
Texte intégral:
Asian Pac J Allergy Immunol
Année:
2001
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS